Volume 141, Issue 3, Pages 881-889.e1 (September 2011) Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections  Graham R. Foster, Christophe Hézode, Jean–Pierre Bronowicki, Giampiero Carosi, Ola Weiland, Lieselotte Verlinden, Rolf van Heeswijk, Ben van Baelen, Gaston Picchio, Maria Beumont  Gastroenterology  Volume 141, Issue 3, Pages 881-889.e1 (September 2011) DOI: 10.1053/j.gastro.2011.05.046 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Summary of patient disposition and outcomes. aThese 3 patients were randomized to the TPR group and were excluded before first intake of study medication. bIncludes confirmed and unconfirmed viral breakthroughs, as described in the Methods section. cPatient had detectable HCV RNA at day 15 (last visit), but was subsequently lost to follow-up (Peg-IFN/RBV provided but intake unknown). dPatient had undetectable HCV RNA at week 12 after EOT, but was subsequently lost to follow-up. eOne patient with detectable HCV RNA at EOT was subsequently lost to follow-up. fOne patient had undetectable HCV RNA at EOT, but did not return for any follow-up visits; 2 patients had undetectable HCV RNA at last visit (weeks 4 and 8 after EOT) but were subsequently lost to follow-up. Gastroenterology 2011 141, 881-889.e1DOI: (10.1053/j.gastro.2011.05.046) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Viral load changes (observed data) over the 2-week investigational treatment phase: (A) all HCV genotype 2 treatment groups (median change); (B) individual patients in the HCV genotype 2 telaprevir monotherapy group; (C) All HCV genotype 3 treatment groups; (median change); and (D) individual patients in the HCV genotype 3 telaprevir monotherapy group. G, genotype; LOQ, limit of quantification. Gastroenterology 2011 141, 881-889.e1DOI: (10.1053/j.gastro.2011.05.046) Copyright © 2011 AGA Institute Terms and Conditions